Continue Your Education

Dr Naomi Dempsey MD, from Miami Cancer Institute comments on the growing availability of targeted therapies, and a corresponding need for NGS and genetic testing in advanced breast cancer: Elacestrant, an oral SERD for ESR1 mutation, alpelisib with endocrine therapy for PIK3CA mutation, the AKT inhibitor capivasertib, and other options following progression on CDK4/6 inhibitors.

Dr Yousseff Zeidan, MD from Lynn Cancer Institute comments on the role of the multidisciplinary team (MDT) in breast cancer care: Interaction and alignment of surgeons, nurses, pathologists, radiologists, social workers, and other specialists to optimize treatment in challenging cases.

Dr Starr Mautner, MD from Miami Cancer Institute comments on the role of the multidisciplinary team in breast cancer management: Integration of breast surgical oncology, medical oncology, and radiation oncology, along with genetic counselors and breast reconstructive surgeons to develop a more personalized approach.

Dr Naomi Dempsey, MD from Miami Cancer Institute comments on the use of circulating tumor DNA (ctDNA) methodologies in breast cancer: Liquid biopsy to detect actionable molecular alterations in the metastatic setting, and a more investigational use in primary breast cancer to monitor for minimal residual disease.

In this session, Dr Naomi Dempsey from Miami Cancer Institute discusses the use of precision medicine in breast cancer.

In this session, Debbie Denardi from Force highlights the role of advocacy organizations in breast cancer.

Dr Komal Jhaveri, MD, FACP, MSK from Memorial Sloan Kettering Cancer Center comments on treatment of metastatic triple negative breast cancer.

Dr Sunil Badve, MD, FRCPath from Emory University comments on the treatment implications of lower HER2 expression levels in breast cancer: Evolving clinical paradigms for ‘HER2 positive’ disease, re-defining ‘triple negative’ status, and a changing landscape of targetable mutations and effective treatments.